Last reviewed · How we verify
Fosfomycin sodium intravenous
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the MurA enzyme, preventing peptidoglycan cross-linking.
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the MurA enzyme, preventing peptidoglycan cross-linking. Used for Serious bacterial infections caused by susceptible pathogens, Multidrug-resistant gram-negative infections.
At a glance
| Generic name | Fosfomycin sodium intravenous |
|---|---|
| Also known as | Generic name: Fosfomycin, Pharmaceutical form: solution for infusion, ATC code: J01J3 |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Drug class | Cell wall synthesis inhibitor |
| Target | MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Fosfomycin is a broad-spectrum antibiotic that acts as a phosphoenolpyruvate (PEP) analogue, irreversibly inhibiting UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), a key enzyme in bacterial peptidoglycan biosynthesis. This disruption of cell wall formation leads to bacterial cell lysis and death. The intravenous sodium formulation allows systemic delivery for treatment of serious infections.
Approved indications
- Serious bacterial infections caused by susceptible pathogens
- Multidrug-resistant gram-negative infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Headache
- Injection site reactions
Key clinical trials
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
- Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection (PHASE4)
- Intravenous Fosfomycin Pharmacokinetics Study (PHASE1)
- PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age) (PHASE1)
- Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli (PHASE3)
- 4-way Crossover QT Evaluation in Healthy Subjects (PHASE1)
- Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients (PHASE4)
- Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: